Araceli P. P.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Study of Adagrasib Versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
- Phase II Evaluation of Repotrectinib Efficacy and Safety in ROS1-Positive NSCLC Patients with Active Brain Metastases
- Phase II Multicenter, Open-Label Study of Datopotamab Deruxtecan in Non-Squamous NSCLC Patients with Active Brain Metastases (TUXEDO-5)
Data & Insights
Has run more than one trial at 7 of 118 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating advanced non-small cell lung cancer, with particular expertise in cases involving specific genetic mutations.
- Targeted cancer therapeutics
- KRAS mutation analysis
- Advanced lung cancer treatment
Research interests center on innovative therapeutic approaches for treating advanced stages of lung cancer.
Precision Medicine
The investigator focuses on personalized treatment strategies based on genetic profiling, particularly in lung cancer patients.
- Molecular targeted therapy
- Genetic mutation analysis
- Biomarker-driven treatment
Expertise includes identifying and treating specific genetic variations in cancer patients.
Treatment Innovation
The investigator explores comparative therapeutic approaches in advanced lung cancer treatment.
- Novel therapeutic agents
- Treatment comparison studies
- Advanced cancer care
Areas of interest include evaluating novel treatments against established therapies in lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.